Nanomedicines for the Prevention and Treatment of Infectious Diseases

Name: Nanomedicines for the Prevention and Treatment of Infectious Diseases
Brand: Springer
Price: 234.33 EUR
Availability: OnlineOnly

Vandana B. Patravale Abhijit A. Date Anil B. Jindal(Herausgeber*in)

Springer (Verlag)

1. Auflage

Erschienen am 31. Oktober 2023

XVI, 404 Seiten

E-Book

PDF mit Wasserzeichen-DRM

Systemvoraussetzungen

978-3-031-39020-3 (ISBN)

234,33 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Wasserzeichen-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

The COVID-19 pandemic has altered the world and reiterated the perpetual need for the development of effective strategies for the prevention and treatment of infectious diseases. While globally prevalent infectious diseases receive extensive attention in terms of drug development and delivery, the neglected and/or emerging infectious diseases that affect developing countries are often overlooked. Additionally, the therapeutic efficacy of existing anti-infective agents is often limited due to sub-optimal biopharmaceutical properties, sub-therapeutic levels of the drugs at the infection site due to various physiological barriers, the expulsion of the drug by efflux transporters, and the emergence of drug-resistant strains.

From the commercialization of AmBisome® to the emergency authorization of mRNA-based vaccines, nanotechnology has played a vital role in the prevention and treatment of infectious diseases. More importantly, nanotechnology has enabled the effective utilization ofexisting armamentarium against infectious diseases leading to improved therapeutic outcomes with a concomitant reduction in the side effects associated with anti-infective agents. In particular, nanotechnology can bring about a paradigm shift in the management of neglected and emerging infectious diseases and may compensate for the lack of drug discovery efforts. While there are several books dedicated to pharmaceutical and/or biomedical applications of nanotechnology or nanotechnology for cancer therapy a comprehensive book focusing on the prevention and/or treatment of viral, bacterial, fungal, and parasitic infections is not available. This book addresses an unmet need in pharmaceutical and medical education.

This book provides a comprehensive and up-to-date overview of the latest advancements in nanomedicine, which show great potential for preventing and treating infectious diseases. Covering a wide range of topics, it explores various formulation strategies for combating microbial, fungal, parasitic, and viral infections. The book emphasizes the advantages of nano-scale vaccines over traditional ones and discusses their production. It also examines feasible treatment approaches for diseases like malaria, trypanosomiasis, candidiasis, Hepatitis B, HIV, and the ongoing COVID-19 pandemic. Additionally, it highlights the role of nano-adjuvants in vaccine development, as well as the use of peptide antibiotics and pulmonary delivery of drugs, which open up new possibilities in fighting infectious diseases. Furthermore, the book explores the critical role of nanomedicine in addressing veterinary parasitic infections. The emergence of nanotechnology has led to novel strategies for diagnosing, treating, and preventing parasitic infections in animals.

In summary, this book offers a comprehensive description of clinically viable and investigational nanotechnology-enabled medicines (nanomedicines) for the prevention and treatment of globally prevalent, neglected, and emerging infectious diseases.

Weitere Details

Weitere Ausgaben

Personen

Prof. Vandana B. Patravale: She is currently a Professor of Pharmaceutics at the Institute of Chemical Technology, Mumbai, India. She has around 30 years of teaching and research experience. She has over 200 refereed publications (h index: 45, i10 index: 109), 15 granted patents, 22 patents in the pipeline, and 2 trademark registries. She has published 2 books and 30 book chapters with international publishers. Dr. Patravale has been active in teaching, research and service throughout her career and has been bestowed with several national and international awards. Her research is focused on the development of nanocarriers with major emphasis on infectious diseases, cancer, and neurodegenerative disorders; medical device development, nanodiagnostics, and nanovaccines.

She is the Vice president-CRS Indian chapter, editorial board member DDTR, editor CRS IC, and APTI women forum newsletters. She is actively collaborating with researchers as well as industries within India andabroad and has transferred about 20 technologies to the industry including drug-eluting stents being marketed in more than 60 countries.

Dr. Abhijit Date: He is currently an Assistant Professor at the Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy (DKICP), University of Hawaii Hilo. He is a pharmaceutical scientist by training with vast experience in the development and pre-clinical evaluation of conventional and novel drug delivery systems including nanomedicines. He is listed as an inventor on 4 US/PCT patents or patent applications. He has 58 peer-reviewed publications (h index: 27), and 4 book chapters to his credit, and his research work have been published in the renowned drug delivery/translational journals like Nature Biomedical Engineering, Clinical Cancer Research, Biomaterials, Journal of Controlled Release, Bioengineering and Translational Medicine, International Journal of Pharmaceutics, ACS Infectious Diseases, andMolecular Pharmaceutics. He received the Johns Hopkins Center for Nanomedicine research excellence award in 2016. He has been a recipient of the DKICP Student Choice Award for Teaching in Pharmaceutical Sciences in 2018, 2019, 2020, and 2021. He serves as the guest editor for AAPSPharmSciTech's special issue on the delivery of natural products and as a reviewer for more than 30 drug delivery journals. Dr. Date's current research work is focused on drug repurposing and reformulation for the treatment of cancer and infectious diseases with limited treatment options.

Dr. Anil Jindal: Dr. Anil Jindal is an Associate Professor at the Department of Pharmacy at the Birla Institute of Technology and Science Pilani Pilani Campus. His research is focused on developing innovative drug delivery systems to treat infectious diseases in both humans and animals. Dr. Jindal holds a PhD from the Institute of Chemical Technology Mumbai and worked with leading pharmaceutical companies such as Pfizer and IPCA Laboratories before joining BITS Pilani. He is the author of numerous publications and book chapters and the inventor of three patent applications in nano-drug delivery systems. He is also an editor of the book "Pharmaceutical Process Engineering and Scale-up Principles", published by Springer as a part of AAPS Introduction in the Pharmaceutical Sciences Series. Dr. Jindal's contributions to the field of drug delivery earned him several prestigious academic awards, including the Prof. M.L. Khorona Memorial Award in 2010, the Eudragit Award in 2018, and the Early Career Research Award in 2019, presented by SERB, Government of India, for his significant contribution to research. Dr. Jindal's interview was recently featured in Voices Editorial of Molecular Pharmaceutics, demonstrating his recognition as a thought leader in his field. Additionally, he has been appointed as a managing theme editor for Advanced Drug Delivery Reviews, a highly respected journal with an impact factor of 17.87.

Inhalt

Systemvoraussetzungen

Als PDF speichern Als Link merken